Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Reslizumab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Reslizumab. Displaying page 1 of 1.
    EudraCT Number: 2016-004459-65 Sponsor Protocol Number: SEP-RES-2016-01 Start Date*: 2017-03-20
    Sponsor Name:Respira. Fundación Española del Pulmón (SEPAR)
    Full Title: Reslizumab in patients with severe asthma who failed to respond to omalizumab: a pilot study
    Medical condition: Severe asthma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002060-40 Sponsor Protocol Number: C38072-AS-10069 Start Date*: 2017-07-11
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Single-Dose, Open-Label, Parallel Group Study to Characterize the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of Reslizumab Following Subcutaneous Administration ...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-002659-25 Sponsor Protocol Number: C38072-AS-30024 Start Date*: 2016-07-04
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: An Open-Label Safety Study of Patients with Severe Eosinophilic Asthma Who Were Previously Enrolled in the Reslizumab Open Label Extension Study C38072/3085
    Medical condition: Treatment for patients with eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-024540-15 Sponsor Protocol Number: C38072/3085 Start Date*: 2011-07-20
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: An Open-Label Extension Study to evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients with Eosinophilic Asthma who completed a prior Cephalon-sponsored Stu...
    Medical condition: Treatment for patients with eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) SE (Completed) CZ (Completed) GR (Completed) HU (Completed) NL (Completed) DK (Prematurely Ended) PL (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2010-023342-67 Sponsor Protocol Number: C38072/3081 Start Date*: 2011-07-20
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) wit...
    Medical condition: Treatment for patients with eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) HU (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-004661-23 Sponsor Protocol Number: C38072-AS-30066 Start Date*: 2017-03-15
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: An Open-Label Extension Safety Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older with Severe Eosinophilic Asthma
    Medical condition: Uncontrolled Asthma & elevated blood Eosinophils
    Disease: Version SOC Term Classification Code Term Level
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Prematurely Ended) CZ (Completed) DE (Prematurely Ended) FR (Completed) ES (Prematurely Ended) PL (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001580-39 Sponsor Protocol Number: C38072-AS-30027 Start Date*: 2015-10-30
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Phase 3, 24-Week Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Reslizumab Subcutaneous Dosing (110 mg Every 4 weeks) in Patients with Oral Corticosteroid Dependen...
    Medical condition: Asthma & elevated blood Eosinophils
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) BE (Completed) ES (Completed) IT (Completed) NL (Completed) PL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-024006-35 Sponsor Protocol Number: C38072/3083 Start Date*: 2011-05-05
    Sponsor Name:Teva Branded Pharmaceutical Products, R&D, Inc.
    Full Title: A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the reduction of Clinical Asthma Exacerbations in Patients (12-75...
    Medical condition: Treatment for patients with eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-024614-66 Sponsor Protocol Number: C38072/3082 Start Date*: 2011-07-20
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc
    Full Title: A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the reduction of Clinical Asthma Exacerbations in Patients (12-75...
    Medical condition: Treatment for patients with eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) CZ (Completed) DK (Completed) HU (Completed) PL (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2015-000865-29 Sponsor Protocol Number: C38072-AS-30025 Start Date*: 2015-10-01
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients with Uncontrolled Asthma and Elevated Blood Eosinophils
    Medical condition: Uncontrolled Asthma & elevated blood Eosinophils
    Disease: Version SOC Term Classification Code Term Level
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Prematurely Ended) HU (Prematurely Ended) BE (Completed) PL (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003358-63 Sponsor Protocol Number: 2020033183. Start Date*: 2020-12-10
    Sponsor Name:Bispebjerg Hospital
    Full Title: OPTIMAL - Titration of treatment with biologics in severe asthma
    Medical condition: Severe asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-003548-22 Sponsor Protocol Number: CLI-06532AA1-01 Start Date*: Information not available in EudraCT
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A 52 week, randomised, double blind, multinational, multicentre, 4-arm parallel group trial to assess the efficacy and safety of 3 doses of CHF 6532 (10, 25 or 50 mg BID) compared to placebo on top...
    Medical condition: Severe Eosinophilic Asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Prematurely Ended) HU (Completed) DE (Ongoing) BG (Prematurely Ended) GR (Completed) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006681-21 Sponsor Protocol Number: FVGEXACT@home2021 Start Date*: 2022-11-17
    Sponsor Name:Franciscus Gasthuis & Vlietland
    Full Title: Expertise Asthma COPD Program with Digital Support
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004855 10003555 Asthma bronchial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 08:34:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA